Novo Holdings

Novo Holdings

Novo Holdings

CNBC Tech

Tempus: Health start-up backed by Groupon co-founder joins the fight against Covid-19

$85,000,000 Venture capital (Series C)
FinSMEs , Pulse 2.0

Checkmate Pharmaceuticals Raises $85M in Series C Financing

$11,500,000 Venture capital
VentureBeat

Kebotix raises $11.5 million to automate lab experiments with AI and robotics

$100,000,000 Venture capital (Series G)
Pulse 2.0

Tempus: $100 Million Funding And $5 Billion Valuation

$88,000,000 Venture capital (Series B)
FinSMEs , Xconomy

Spruce Biosciences Raises $88M in Series B Financing

€11,000,000 Venture capital (Series B)
FinSMEs

HepaRegeniX Closes Over €11M Series B Financing round

$72,000,000 Venture capital (Series E)
FinSMEs

LanzaTech Receives $72M Investment from Novo

PE HUB

LanzaTech amasses $72 mln

TechCrunch

Through a new partnership and $72 million in funding, LanzaTech expands its carbon capture tech

$200,000,000 Venture capital
TechCrunch , TechCrunch

Groupon cofounder Eric Lefkofsky just raised another $200 million for his newest company, Tempus

FinSMEs

Pfizer Acquires Clinical-Stage Biotech Company Therachon, for Up To $810M

$67,000,000 Venture capital (Series A)
FinSMEs

Inozyme Pharma Raises $67M in Series A2 Financing

$22,000,000 Venture capital (Series C)
FinSMEs

Checkmate Pharmaceuticals Closes $22M Financing

$5,000,000 Seed fund
FinSMEs

Kebotix Raises $5m in Seed Funding

Robotics Funding Intelligent machines
$80,000,000 Venture capital
FinSMEs

Milestone Pharmaceuticals Raises $80M in Equity Funding

Funding Health
$80,000,000 Venture capital (Series B)
FinSMEs , PE HUB , Xconomy

Morphic Therapeutic Raises $80M in Series B Financing

Funding Health
$110,000,000 Venture capital (Series E)
FinSMEs , PE HUB

Tempus Raises $110M in Series E Financing

Funding Cloud Health
$60,000,000 Venture capital (Series B)
FinSMEs

Biotech Company Therachon Raises $60M Mezzanine Financing

Funding Health
$70,000,000 Venture capital (Series C)
PE HUB , TechCrunch

NEA and Revolution Growth leads Series C round for Tempus

$27,000,000 Venture capital (Series B)
businesswire , PE HUB , ENDPOINTS NEWS

Checkmate Pharmaceuticals Secures $27 Million Series B Preferred Financing and Appoints Karen Brennan as Chief Operating...